Celldex announces barzolvolimab met all primary and secondary endpoints in phase 2 study for chronic inducible urticaria
- Barzolvolimab showed positive results in a Phase 2 trial for chronic inducible urticaria (CIndU), meeting all primary and secondary endpoints.
- The study involved 196 patients with CIndU, focusing on cold urticaria and symptomatic dermographism, who were unresponsive to antihistamines.
- Barzolvolimab demonstrated significant improvements in critical temperature and friction thresholds, with a favorable safety profile.
- Celldex plans to advance barzolvolimab into Phase 3 development for CIndU in 2025.
Read more
